Axovant Sciences Ltd. (AXON) announced Tuesday morning that its Phase 3 trial of intepirdine, in patients with mild to moderate Alzheimer's disease who were receiving background donepezil therapy, failed to meet its co-primary efficacy endpoints.
from RTT - Before the Bell http://ift.tt/2xvCcNe
via IFTTT
No comments:
Post a Comment